D007069Chemicals & DrugsD02.455.526.728.650.730.243.250D02.705.672.500.243.250D03.383.533.500880.997513IfosfamideFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson17639396Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco ACancer chemotherapy and pharmacologyGemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol. 2008 Apr; 61(5):803-7.Cancer Chemother Pharmacol2007-07-18T00:00:002007Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.true1ProfessorProfessorRadiation OncologyStevenGitelisSteven Gitelis41.87352120000000-87.66713820000000349068Gitelis, StevenProfessorSunitaNathanSunita Nathan349468Nathan, SunitaAssistant ProfessorMartaBatusMarta Batus349586Batus, MartaAssociate ProfessorRossAbramsRoss Abrams349600Abrams, RossProfessorChristopherSederChristopher Seder349647Seder, ChristopherAssistant Professor6Assistant Professor5Associate Professor4Professor26504071Gallo K, Brickman A, Warren WH, Gattuso P, Seder CWAnticancer researchUnresectable Middle Mediastinal Biphasic Pulmonary Blastoma. Anticancer Res. 2015 Nov; 35(11):6325-7.Anticancer Res2015-11-01T00:00:002015Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma.0.1734580.008503148research area of0.2347350.03409747subject area forOrthopedic SurgeryRush University, Rush Medical CollegeCardiovascular and Thoracic SurgeryInternal Medicine, Division of Hematology/Oncology/Cell Therapytrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor36928527Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JNJAMA oncologyPembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.JAMA Oncol2023-05-01T00:00:002023Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.28475457Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RDJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35(20):2260-2267.J Clin Oncol2017-05-05T00:00:002017Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.29782358Chowdhary M, Sen N, Jeans EB, Miller L, Batus M, Gitelis S, Wang D, Abrams RAAmerican journal of clinical oncologyNeoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2019 01; 42(1):1-5.Am J Clin Oncol2019-01-01T00:00:002019Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.